| Pharmacokinetics, Safety and Tolerability of the Preservative-free Fixed Dose Combination of Tafluprost 0.0015% and Timolol 0.5% Eye Drops (NCT01434888) | Santen Oy | 2011-09-01 |
| Safety and Pharmacokinetics of Single and Multiple Dose Rifampin in Infants (NCT01441206) | University of North Carolina, Chapel Hill | 2011-09-01 |
| Phase I Dose Escalation Study of the Safety and Pharmacokinetics of ME-143 Single Agent for Refractory Solid Tumors (NCT01401868) | MEI Pharma, Inc. | 2011-09-01 |
| A Study on Safety, Pharmacokinetics and Pharmacodynamics of RO5508887 in Healthy Volunteers (NCT01461967) | Hoffmann-La Roche | 2011-09-01 |
| Effect of Adjuvant & Route of Administration on Safety & Immunogenicity of NDV-3 Vaccine (NCT01447407) | NovaDigm Therapeutics, Inc. | 2011-09-01 |
| INSORB Versus Subcuticular Sutures at Cesarean Section (NCT01687972) | Johns Hopkins University | 2011-09-01 |
| Dasatinib and Cyclosporine in Treating Patients With Chronic Myelogenous Leukemia Refractory or Intolerant to Imatinib Mesylate (NCT01426334) | National Cancer Institute (NCI) | 2011-09-01 |
| Cedar Honey in Oral Lichen Planus (NCT01974414) | Mashhad University of Medical Sciences | 2011-09-01 |
| PK Study of ACHN-490 Injection in Renally Impaired Subjects (NCT01462136) | Achaogen, Inc. | 2011-09-01 |
| AT9283 in Treating Young Patients With Relapsed or Refractory Acute Leukemia (NCT01431664) | Cancer Research UK | 2011-09-01 |
| Study to Assess the Pharmacokinetics of Cabozantinib (XL184) in Hepatic Impaired Adult Subjects (NCT01493869) | Exelixis | 2011-09-01 |
| Remote Ischemic Preconditioning Prior to Vascular Surgery (NCT01558596) | VA Office of Research and Development | 2011-09-01 |
| Drug Interaction and Safety Between Valsartan and Rosuvastatin in Healthy Male Volunteers (NCT01918709) | LG Life Sciences | 2011-09-01 |
| Fibrinogen Concentrate (FGTW) in Trauma Patients, Presumed to Bleed (FI in TIC) (NCT01475344) | Medical University Innsbruck | 2011-09-01 |
| A Drug-Drug Interaction Study of Omeprazole and PA21 (NCT01452906) | Vifor Pharma | 2011-09-01 |
| Human Repeated Insult Patch Test (HRIPT) of Azelaic Acid Pre Foam Formulation (NCT01430533) | LEO Pharma | 2011-09-01 |
| Akt Inhibitor MK2206, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (NCT01369849) | National Cancer Institute (NCI) | 2011-09-01 |
| Intra-hepatic Artery Bone Marrow Derived Stem Cells Infusion for the Treatment of Advanced Liver Cirrhosis (NCT01412593) | King Saud University | 2011-09-01 |
| Safety Study of Anti-Influenza Virus Monoclonal Antibody to Treat Influenza (NCT01390025) | Theraclone Sciences, Inc. | 2011-09-01 |
| Trial to Evaluate Safety and Tolerability of ALN-PCS02 in Subjects With Elevated LDL-Cholesterol (LDL-C) (NCT01437059) | Alnylam Pharmaceuticals | 2011-09-01 |
| Evaluation of Clinical Safety of Combining Metformin With Anticancer Chemotherapy (NCT01442870) | Tufts Medical Center | 2011-09-01 |
| A Study to Describe the Pharmacokinetics of Acyclovir in Premature Infants (PTN_Acyclo) (NCT00942084) | Phillip Brian Smith | 2011-09-01 |
| The Effect of BIA 9-1067 at Steady-state on the Levodopa Pharmacokinetics (NCT02170376) | Bial - Portela C S.A. | 2011-09-01 |
| A Single Oral Dose Study of ASP015K in Healthy Volunteers Assessing the Relative Bioavailability Across Three Tablet Strengths From a New Formulation of ASP015K (NCT01486017) | Astellas Pharma Inc | 2011-09-01 |
| A Study of Intradermal Administration of ZOSTAVAX™ (V211-051 AM2) (NCT01385566) | Merck Sharp & Dohme LLC | 2011-09-01 |
| A Trial to Assess the Safety, Tolerability, and Pharmacokinetics of MDT-637 in Healthy Volunteers (NCT01355016) | MicroDose Therapeutx, Inc | 2011-09-01 |
| A Phase 1 Study of SP-02L in Relapsed or Refractory Patients With Peripheral T-cell Lymphoma (PTCL) (NCT01435863) | Solasia Pharma K.K. | 2011-09-01 |
| MSC2015103B in Solid Tumors (NCT01453387) | EMD Serono | 2011-09-01 |
| In Vitro Expanded Allogeneic Epstein-Barr Virus Specific Cytotoxic T-Lymphocytes (EBV-CTLs) Genetically Targeted to the CD19 Antigen in B-cell Malignancies (NCT01430390) | Memorial Sloan Kettering Cancer Center | 2011-09-01 |
| Two Formulations of ELAPR Compared to Restylane® Vital Light Following Repeat Implants in the Upper Arm Dermis (NCT01466413) | Elastagen Pty Ltd | 2011-09-01 |
| Study of Antibiotics in Cerebrospinal Fluid Following Intravenous Injection (NCT00925093) | Aarhus University Hospital | 2011-09-01 |
| A Phase I Dose Escalation Study of Plerixafor in Healthy Subjects of Japanese Descent (NCT01579149) | Genzyme, a Sanofi Company | 2011-09-01 |
| Study to Assess the Effects of Mipomersen on Lipid and Lipoprotein Metabolism in Healthy Subjects (NCT01414881) | Kastle Therapeutics, LLC | 2011-09-01 |
| Age and Gender Effects on the Pharmacokinetics of BAY85-3934 (NCT01458028) | Bayer | 2011-09-01 |
| A Study of the Effect of Dulaglutide on the Action of Warfarin in Healthy Participants (NCT01432938) | Eli Lilly and Company | 2011-09-01 |
| Phase I Clinical Trial in Healthy Male Volunteers (NCT03860532) | Hutchison Medipharma Limited | 2011-09-01 |
| A Study to Assess the Bioequivalence of 2 Fixed Dose Combination (FDC) Tablets of Canagliflozin and Metformin Immediate Release (IR) (150 mg/850 mg) With Respect to the Individual Components of Canagliflozin (1 x 300 mg) and Metformin IR Tablets (2 x 850 mg) in Healthy Volunteers (NCT01518712) | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | 2011-09-01 |
| Phase I Trial of Combination of FOLFIRI and SOM 230 (NCT01434069) | H. Lee Moffitt Cancer Center and Research Institute | 2011-09-01 |
| Clinical Trial I/II Opened, Randomized and Controlled for the Study of the Use of Stem Cells Therapy in Insulinized Diabetic Patients Type 2 With Critical Ischemia in Lower Limbs (CLI): Study of the Needs of Insulin (NCT02287974) | Andalusian Initiative for Advanced Therapies - Fundación Pública Andaluza Progreso y Salud | 2011-09-01 |
| Vitamin E δ-Tocotrienol (VEDT) Single Dose in Healthy Subjects (NCT01446952) | H. Lee Moffitt Cancer Center and Research Institute | 2011-09-01 |
| The Effects of Urinary pH Changes on an Investigational Compound in Healthy Subjects (NCT01440478) | Eli Lilly and Company | 2011-09-01 |
| A Study of the Effect of Dulaglutide on How Body Handles Digoxin in Healthy Participants (NCT01436201) | Eli Lilly and Company | 2011-09-01 |
| Safety of Lactobacillus Rhamnosus GG Vs. Placebo in Elderly Subjects Receiving Trivalent Inactivated Influenza Vaccine (NCT01368029) | Massachusetts General Hospital | 2011-09-01 |
| Safety/Efficacy Study: OPA-6566 Ophthalmic Solution in Subjects With Primary Open-Angle Glaucoma or Ocular Hypertension (NCT01410188) | Kubota Vision Inc. | 2011-09-01 |
| E2022 Patch Formulation Multiple Dose Study (NCT01450839) | Eisai Co., Ltd. | 2011-09-01 |
| Arsenic Trioxide and Tyrosine Kinase Inhibitors for Chronic Myelogenous Leukemia (CML) (NCT01397734) | Beth Israel Deaconess Medical Center | 2011-09-01 |
| Stem Cell Therapy in Mental Retardation (NCT02245724) | Neurogen Brain and Spine Institute | 2011-09-01 |
| Evaluation of [18F]MPPF as a Brain Tracer of Serotonin Receptor 5HT1a (NCT01461083) | Institute for Neurodegenerative Disorders | 2011-09-01 |
| PEP005 Gel - Biological Effects in Actinic Keratosis Assessed by Reflectance Confocal Microscopy (NCT01449513) | LEO Pharma | 2011-09-01 |
| Haploidentical Donor Natural Killer Cell Infusion With IL-15 in Acute Myelogenous Leukemia (AML) (NCT01385423) | Masonic Cancer Center, University of Minnesota | 2011-09-01 |
| Study of Gemcitabine With TheraSphere® (Yttrium-90)in Patients With Hepatic Tumors of Pancreatobiliary Origin (NCT01434459) | Emory University | 2011-09-01 |
| Safety Study of 2.0mg Lucentis to Treat Polypoidal Choroidal Vasculopathy (NCT01469156) | Southeast Retina Center, Georgia | 2011-09-01 |
| A Study to Determine the Safety and Efficacy of LX3305 in Subjects With Active Rheumatoid Arthritis (NCT01417052) | Lexicon Pharmaceuticals | 2011-09-01 |
| Bioavailability Study of Amlodipine Besylate/Atorvastatin Calcium Tablets 10/80 mg Under Fed Condition (NCT02292069) | Dr. Reddy's Laboratories Limited | 2011-09-01 |
| AC220 for Children With Relapsed/Refractory ALL or AML (NCT01411267) | Therapeutic Advances in Childhood Leukemia Consortium | 2011-09-01 |
| A Brief Educational Intervention to Improve Traumatic Brain Injury (TBI) Screening Outcomes (NCT01558791) | VA Office of Research and Development | 2011-09-01 |
| Study of Gemcitabine + PEGPH20 vs Gemcitabine Alone in Stage IV Previously Untreated Pancreatic Cancer (NCT01453153) | Halozyme Therapeutics | 2011-09-01 |
| Anti-CXCR4 (BMS-936564) Alone and in Combination With Lenalidomide/Dexamethasone or Bortezomib/Dexamethasone in Relapsed/Refractory Multiple Myeloma (NCT01359657) | Bristol-Myers Squibb | 2011-09-01 |
| Xenogenic Keratoplasty From Porcine Cornea (NCT01443559) | Xiamen University | 2011-09-01 |
| Autophagy Inhibition to Augment Mammilian Target of Rapamycin (mTOR) Inhibition: A Phase I/II Trial of RAD001 and Hydroxychloroquine (HCQ) in Patients With Previously Treated Renal Cell Carcinoma (NCT01510119) | Abramson Cancer Center at Penn Medicine | 2011-09-01 |
| Elucidating Kisspeptin Physiology by Blocking Kisspeptin Signaling (NCT01438073) | Massachusetts General Hospital | 2011-09-01 |
| Effect of Tadalafil on Exercise Capacity in Pediatric Fontan Patients (NCT01291069) | University of Utah | 2011-09-01 |
| A Study of the Safety and Pharmacokinetics of JNJ-38518168 in Japanese and Caucasian Male Participants and the Effect of JNJ-38518168 on the Blood Levels of Midazolam (NCT01442532) | Janssen Research & Development, LLC | 2011-09-01 |
| A Phase I, Randomized, Single-Blind, Four-Period Cross-Over, Placebo-Controlled, Dose-Escalation Study to Evaluate the Safety and Pharmacokinetics of Single Oral Doses of GR181413A/AT1001 in Healthy Japanese Subjects (NCT01853852) | Amicus Therapeutics | 2011-09-01 |
| Pharmacokinetics and Distribution of Dapsone in Leucocytes After Single-dose and Multiple-dose Administration (NCT02493283) | University Medicine Greifswald | 2011-09-01 |
| Safety and Efficacy Study of Hypofractionated Radiotherapy and Androgen Deprivation Therapy for Prostate Cancer (NCT01505075) | Sunnybrook Health Sciences Centre | 2011-09-01 |
| An Enhanced Medication Monitoring Program (NCT01105104) | MedMinder Systems Inc. | 2011-09-01 |
| Safety and Tolerability Study of SNS01-T in Relapsed or Refractory B Cell Malignancies (Multiple Myeloma, B Cell Lymphoma, or Plasma Cell Leukemia (PCL) (NCT01435720) | Senesco Technologies, Inc. | 2011-09-01 |
| Lapatinib and Bortezomib in Patients With Advanced Malignancies (NCT01497626) | Georgetown University | 2011-09-01 |
| Experimental Biomarker Study for Pain Thresholds (NCT02695745) | Purdue Pharma LP | 2011-09-01 |
| Immune Response to Systemic and Mucosal Antigenic Challenge in the Presence of Vedolizumab (NCT01981616) | Millennium Pharmaceuticals, Inc. | 2011-09-01 |
| A Study of LY3015014 in Healthy Participants With Elevated Low Density Lipoprotein Cholesterol (NCT01426412) | Eli Lilly and Company | 2011-09-01 |
| Safety, Tolerability, Pharmacokinetics and Antiviral Activity of GS-9669 in Subjects With Chronic Hepatitis C Virus Infection (NCT01431898) | Gilead Sciences | 2011-09-01 |
| Study of TKI 258 in Combination With Xeloda and Oxaliplatin in Advanced Colorectal and Gastric Cancer (NCT02720926) | National Cancer Centre, Singapore | 2011-09-01 |
| A Study of Continuous Endostar Intravenous Infusion Combined With Pemetrexed and Carboplatin in Advanced Non Small Cell Lung Cancer Patients (NCT01531790) | Jiangsu Simcere Pharmaceutical Co., Ltd. | 2011-09-01 |
| GS-7977 With Ribavirin for Hepatitis C (SPARE) (NCT01441180) | National Institute of Allergy and Infectious Diseases (NIAID) | 2011-09-01 |
| Pharmacokinetics & Safety Study of Clopidogrel 75mg and Aspirin 100mg Coadministration (NCT01526122) | Dong-A ST Co., Ltd. | 2011-09-01 |
| Single Ascending Oral Dose Phase I Study With Px-102 (NCT01998659) | Phenex Pharmaceuticals AG | 2011-09-01 |
| Safety of Tuberculosis Vaccine, MVA85A, Administered by the Aerosol Route and the Intradermal Route (NCT01497769) | University of Oxford | 2011-09-01 |
| Autologous Mesenchymal Stem Cells vs. Chondrocytes for the Repair of Chondral Knee Defects (NCT01399749) | Fundacion para la Investigacion Biomedica del Hospital Universitario la Paz | 2011-09-01 |
| Phase I/IIa AdCD40L Immunogene Therapy for Malignant Melanoma and Other Solid Tumors (NCT01455259) | Uppsala University | 2011-09-01 |
| 21 Day Irritancy Test of Azelaic Acid Pre-foam Formulation (NCT01430312) | LEO Pharma | 2011-09-01 |
| Study of the Opioid Modulation of the Effect of Alcohol on the Dopaminergic Reward System (NCT03854942) | RWTH Aachen University | 2011-08-30 |
| Assessment of the Pharmacokinetics of GSK1278863 and Metabolites in Normal Subjects and Subjects With Renal Impairment (NCT01406340) | GlaxoSmithKline | 2011-08-30 |
| Effect of Multiple Dose Levels of SRT2379 on Endotoxin-Induced Inflammation (NCT01416376) | Sirtris, a GSK Company | 2011-08-30 |
| Bioequivalence Study for an Isotretinoin (NCT01863615) | GlaxoSmithKline | 2011-08-26 |
| TKM 080301 for Primary or Secondary Liver Cancer (NCT01437007) | National Cancer Institute (NCI) | 2011-08-26 |
| Inotuzumab Ozogamicin and Combination Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia (NCT01371630) | M.D. Anderson Cancer Center | 2011-08-26 |
| A Phase 1 Study To Investigate The Pharmacokinetics, Safety And Tolerability Of CP-601,927 In Healthy Japanese Subjects (NCT01396135) | Pfizer | 2011-08-26 |
| Effects of Rapid-Resisted Exercise and Bright Light Therapy on Ambulatory Adults With Traumatic Brain Injury (NCT01175993) | National Institutes of Health Clinical Center (CC) | 2011-08-24 |
| Phase I Study of PI3(Phosphoinositol 3)-Kinase Inhibitor BAY80-6946 With Paclitaxel in Patients With Advanced Cancer (NCT01411410) | Bayer | 2011-08-24 |
| FOLFIRINOX Plus IPI-926 for Advanced Pancreatic Adenocarcinoma (NCT01383538) | Andrew Ko | 2011-08-23 |
| Consolidation Therapy With Autologous T Cells Genetically Targeted to the B Cell Specific Antigen CD19 in Patients With Chronic Lymphocytic Leukemia Following Upfront Chemotherapy With Pentostatin, Cyclophosphamide and Rituximab (NCT01416974) | Memorial Sloan Kettering Cancer Center | 2011-08-22 |
| A Study of the Safety, Tolerability, Pharmacokinetics (What the Body Does to the Drug), and Pharmacodynamics (What the Drug Does to the Body) of CNTO 1959 Following a Single Subcutaneous (Under the Skin) Administration in Japanese Participants With Moderate to Severe Plaque Psoriasis (NCT01484587) | Janssen Pharmaceutical K.K. | 2011-08-22 |
| Metronidazole Drug Interaction Study With MMX® Mesalazine/Mesalamine (NCT01418365) | Shire | 2011-08-22 |
| [18F]MK-3328 as a Possible Novel Positron Emission Tomography (PET) Tracer for the Detection of Brain Amyloid Plaques (MK-3328-002) (NCT01385033) | Merck Sharp & Dohme LLC | 2011-08-19 |
| Study of MK-8808 for Participants With Follicular Lymphoma (MK-8808-001) (NCT01370694) | Merck Sharp & Dohme LLC | 2011-08-19 |
| Toll-like Receptor (TLR) 7 Agonist, Cyclophosphamide, and Radiotherapy for Breast Cancer With Skin Metastases (NCT01421017) | NYU Langone Health | 2011-08-19 |
| Japanese BAY80-6946 Monotherapy Phase I Study (NCT01404390) | Bayer | 2011-08-18 |
| Phase I/IIA Study of CART19 Cells for Patients With Chemotherapy Resistant or Refractory CD19+ Leukemia and Lymphoma (NCT01626495) | University of Pennsylvania | 2011-08-17 |